Work

Psoriasis caused by camrelizumab in a patient with esophageal cancer: a case report

Year: 2025

Type: article

Abstract: Immune checkpoint inhibitors (ICIs) are an emerging treatment strategy for cancer, working by activating T cells to suppress tumor growth. However, they can cause immune-related adverse events (irAEs), including psoriasis. We report a case of a patient with esophageal cancer who developed psoriasis 6 weeks after starting camrelizumab. The condition improved following the discontinuation of camrelizumab and treatment with a topical glucocorticoid and a vitamin D3 derivative ointment. At 6-month follow-up, the patient showed no recurrence of psoriatic lesions or tumor progression.

Source: Frontiers in Medicine

DOI: 10.3389/fmed.2025.1647297

Authors: Yimei Duan, Jie Chen, Dongsheng Zhong, Xincai Xiong

Institution: Affiliated Hospital of North Sichuan Medical College

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801